09:48 AM EST - Spectral Diagnostics Inc. : announced that the Data Safety Monitoring Board has evaluated the safety, efficacy and futility of its EUPHRATES trial based on actual data for 184 randomized patients followed for 28 days. Spectral Diagnostics Inc.
shares T.SDI are trading down $0.095 at $0.47.
